Resminostat - 4SC

Drug Profile

Resminostat - 4SC

Alternative Names: 4SC-201; BYK 408740; RAS 2410; YHI-1001

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nycomed
  • Developer 4SC; Yakult Honsha
  • Class Antineoplastics; Dimethylamines; Hydroxylamines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Cutaneous T cell lymphoma; Hepatocellular carcinoma; Hodgkin's disease; Mycosis fungoides; Non-small cell lung cancer; Pancreatic cancer; Sezary syndrome
  • Phase I/II Colorectal cancer
  • Preclinical Diffuse large B cell lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 28 Jun 2018 Pharmacodynamics data from a preclinical trial in Cutaneous T-cell lymphoma released by 4SC AG
  • 27 Mar 2018 Phase-II clinical trials in Cutaneous T-cell lymphoma (Late-stage disease, Second-line therapy or greater) in Japan (PO) (NCT02953301)
  • 27 Mar 2018 Phase-II RESMAIN trial in Sezary syndrome (Late-stage disease, Second-line therapy or greater) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top